MTAP and cancer: Today, we know that loss of MTAP expression is frequent (>10%) in a large number of different human cancers, including glioblastoma, mesothelioma, bladder cancer, pancreatic adenocarcinoma, head and neck cancer, non–small cell lung cancer, melanoma, and diffuse large-cell lymphoma (Fig. S1B).